Ruderfer DM, Fanous AH, Ripke S, et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol Psychiatry. 2014;19(9):1017-24. doi:10.1038/mp.2013.138
Tukiainen T, Pirinen M, Sarin AP, et al. Chromosome X-wide association study identifies Loci for fasting insulin and height and evidence for incomplete dosage compensation. PLoS Genet. 2014;10(2):e1004127. doi:10.1371/journal.pgen.1004127
Helming KC, Wang X, Wilson BG, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med. 2014;20(3):251-4. doi:10.1038/nm.3480
Wilson BG, Helming KC, Wang X, et al. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation. Mol Cell Biol. 2014;34(6):1136-44. doi:10.1128/MCB.01372-13
Knoechel B, Roderick JE, Williamson KE, et al. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. Nat Genet. 2014;46(4):364-70. doi:10.1038/ng.2913
Kool M, Jones DTW, Jäger N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25(3):393-405. doi:10.1016/j.ccr.2014.02.004
Schaffer AE, Eggens VRC, Çağlayan AO, et al. CLP1 founder mutation links tRNA splicing and maturation to cerebellar development and neurodegeneration. Cell. 2014;157(3):651-63. doi:10.1016/j.cell.2014.03.049
Yamamoto S, Wu Z, Russnes HG, et al. JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell. 2014;25(6):762-77. doi:10.1016/j.ccr.2014.04.024
Tang Y, Gholamin S, Schubert S, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014;20(7):732-40. doi:10.1038/nm.3613
Schrader KA, Stratton KL, Murali R, et al. Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. J Clin Oncol. 2016;34(8):e61-7. doi:10.1200/JCO.2013.50.0272